A phase 1/2 trial shows strong early efficacy for daraxonrasib plus chemotherapy as first-line treatment for patients with metastatic pancreatic cancer — but toxicity is a concern.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/daraxonrasib-combo-shows-promise-first-line-mpdac-2026a1000d0k?src=rss
Author :
Publish date : 2026-04-24 06:50:00
Copyright for syndicated content belongs to the linked Source.
